• Conference Recording
  • On-Demand
  • Special Populations
  • Surgery
  • Practice Management
  • Adiposity Related Diseases
  • Physical Activity
  • Pharmacotherapy
  • Patient Assessment
Obesity Medicine 2023 - Spring Obesity Summit 
  • 22.50 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Special Populations
This session utilizes a direct instructional format to expand on the recent American Academy of Pediatrics Clinical Practice Guidelines for the Evaluation and Treatment of Children and Adolescents
  • 0.75 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Behavioral Modification
This case-based instructional session will be presented by quadruple board-certified psychiatrist, Dr. Tiffani Bell Washington and Dr. Sylvia Gonsahn-Bollie.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Adiposity Related Diseases
This session covers new AASLD guidelines for screening, disease associations, diagnosis, and treatments.CME/CE Expiration Date: 10/27/26
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Practice Management
This presentation will provide clinicians a brief scientific overview of 10 of the most controversial topics covered, discussed, and published in OMA’s Clinical Practice Statements, including:
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Special Populations
Dr. Myriam Modestin-Sorrentino will speak on the need to raise awareness and understanding how the the obesity affects maternal and fetal health.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Adiposity Related Diseases
Treatment of people with unhealthy weight has typically focused on those with obesity or in those with BMI ≥ 27 with existing comorbidities; however, evidence indicates that the negative effects of
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
  • 1.25 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
  • 1.00 AMA PRA Category 1 Credit

Pages